Loading stock data…
UNCY
$7.67+0.01 (+0.13%)
Market ClosedLast close May 1
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Unicycive Therapeutics, Inc. in the Healthcare sector is trading at $7.67. The stock is currently 30% below its 52-week high of $11.00, remaining 36.7% above its 200-day moving average. Technical signals show neutral RSI of 69 and bullish MACD crossover, explaining why UNCY maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 69) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.67
Potential Upside
5%
Whystock Fair Value$8.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$43.46+466.6%
Range$15.00 – $90.00
Fundamentals
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$194.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.27%
Volume
Today's trading volume
483,197
Recent News
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well
Key Insights Unicycive Therapeutics' significant retail investors ownership suggests that the key decisions are...
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit?
We feel now is a pretty good time to analyse Unicycive Therapeutics, Inc.'s ( NASDAQ:UNCY ) business as it appears the...
Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m
Key Insights The considerable ownership by retail investors in Unicycive Therapeutics indicates that they collectively...